Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial

BACKGROUND: Class II histone deacetylase (HDAC) inhibitors induce hypoxia-inducible factor-1 and -2α degradation and have antitumour effects in combination with vascular endothelial growth factor (VEGF) inhibitors. In this study, we tested the safety and efficacy of the HDAC inhibitor vorinostat and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pili, Roberto, Liu, Glenn, Chintala, Sreenivasulu, Verheul, Hendrick, Rehman, Shabnam, Attwood, Kristopher, Lodge, Martin A, Wahl, Richard, Martin, James I, Miles, Kiersten Marie, Paesante, Silvia, Adelaiye, Remi, Godoy, Alejandro, King, Serina, Zwiebel, James, Carducci, Michael A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379145/
https://www.ncbi.nlm.nih.gov/pubmed/28222071
http://dx.doi.org/10.1038/bjc.2017.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379145/
https://www.ncbi.nlm.nih.gov/pubmed/28222071
http://dx.doi.org/10.1038/bjc.2017.33

Ejemplares similares